CFAH VHIO – Vall d'Hebron Institute of Oncology

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

  • Dra. Teresa Macarulla
  • Dra. Helena Verdaguer

Matched targeted treatment based on ESCAT actionable genomic alterations associates with improved prognosis of cholangiocarcinoma patients

18/01/2022|Comments Off on Matched targeted treatment based on ESCAT actionable genomic alterations associates with improved prognosis of cholangiocarcinoma patients

Novel microprotein unmasked as a regulator of neural differentiation & neurite formation via calcium dynamics

11/01/2022|Comments Off on Novel microprotein unmasked as a regulator of neural differentiation & neurite formation via calcium dynamics

Emerging approaches for treating gastroesophageal adenocarcinoma: the pitfalls, progress & promise ahead

31/12/2021|Comments Off on Emerging approaches for treating gastroesophageal adenocarcinoma: the pitfalls, progress & promise ahead

VHIO ‘on the ground’ at ASH 2021: seeking out more effective treatment strategies against B-cell lymphomas

23/12/2021|Comments Off on VHIO ‘on the ground’ at ASH 2021: seeking out more effective treatment strategies against B-cell lymphomas

Elena Garralda’s latest ESMO On target column: delving into dietary effects on tumor metabolism & progression

16/12/2021|Comments Off on Elena Garralda’s latest ESMO On target column: delving into dietary effects on tumor metabolism & progression

KEYNOTE-811: pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer

15/12/2021|Comments Off on KEYNOTE-811: pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS